SCHEMBL29901541

SCHEMBL29901541

Fc1ccc(-c2ccccn2)c(F)c1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.50
LMNA P02545 3/20 0.50
CCR1 P32246 3/20 0.50
CCR5 P51681 3/20 0.50
CCR8 P51685 3/20 0.50
CYP1A2 P05177 1/20 0.50
POLB P06746 1/20 0.50
METAP1 P53582 1/20 0.50
BLM P54132 1/20 0.50
HIF1A Q16665 1/20 0.50
DOHH Q9BU89 1/20 0.50
P4HTM Q9NXG6 1/20 0.50
CBFB Q13951 2/20 0.44
RAB9A P51151 5/20 0.43
NPC1 O15118 4/20 0.43
TP53 P04637 3/20 0.43
TDP1 Q9NUW8 2/20 0.43
ALOX15 P16050 2/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1356335 1.00 KDM4E (0.50) KDM4ELMNACCR1CCR5CCR8
SCHEMBL29914907 0.85 KDM4E (0.46) KDM4ELMNACCR1CCR5CCR8
SCHEMBL30888806 0.84 KDM4E (0.50) KDM4ELMNACCR1CCR5CCR8
SCHEMBL970044 0.84 KDM4E (0.50) KDM4ELMNACCR1CCR5CCR8
SCHEMBL12828418 0.83 KDM4E (0.45) KDM4ELMNACCR1CCR5CCR8
SCHEMBL28650048 0.83 KDM4E (0.45) KDM4ELMNACCR1CCR5CCR8
SCHEMBL29986376 0.83 FFAR1 (0.41) KDM4ELMNACCR1CCR5CCR8
SCHEMBL5845748 0.82 CBFB (0.50) KDM4ELMNACCR1CCR5CCR8
SCHEMBL30022590 0.82 KDM4E (0.48) KDM4ELMNACCR1CCR5CCR8
SCHEMBL29986122 0.82 KDM4E (0.48) KDM4ELMNACCR1CCR5CCR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312353-B2 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NOVARTIS AG (CH) 2025-05-27 US disclosed
US-20230002388-A1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) 2023-01-05 US disclosed
US-11420970-B1 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NOVARTIS AG (CH) 2022-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12312353-B2 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NSD2, NSD1, NSD3 KDM4E 769/4885LMNA 3272/4885CCR1 3565/4885
US-11420970-B1 Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents NSD2, NSD1, NSD3 KDM4E 769/4885LMNA 3272/4885CCR1 3565/4885
US-20230002388-A1 PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS NSD2, NSD1, NSD3 KDM4E 769/4885LMNA 3272/4885CCR1 3565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.